Copyright
©The Author(s) 2018.
World J Clin Oncol. Apr 10, 2018; 9(2): 33-41
Published online Apr 10, 2018. doi: 10.5306/wjco.v9.i2.33
Published online Apr 10, 2018. doi: 10.5306/wjco.v9.i2.33
Table 2 Association between response and Clinical-pathological features regarding molecular subtype n (%)
| Lum A | Lum B | HER2 | TN | |||||||||
| Total | pCR | P value | Total | pCR | P value | Total | pCR | P value | Total | pCR | P value | |
| 107 | 13 | 165 | 12 | 77 | 10 | 86 | 13 | |||||
| Age (yr) | 1.000 | 0.315 | 0.507 | 0.157 | ||||||||
| median (range) | 47 (28-75) | 46 (28-62) | 51 (25-84) | 52 (39-69) | 51 (28-80) | 46 (29-80) | 49 (26-73) | 45 (28-68) | ||||
| < 50 | 72 (67) | 9 (13) | 78 (48) | 4 (5) | 37 (48) | 6 (16.2) | 44 (48) | 9 (20) | ||||
| ≥ 50 | 35 (33) | 4 (11) | 87 (52) | 8 (9) | 40 (52) | 4 (10) | 42 (52) | 4 (10) | ||||
| Histological subtypes | 0.349 | 1.000 | 0.434 | 0.392 | ||||||||
| Ductal | 97 (91) | 11 (11) | 153 (93) | 11 (7) | 73 (95) | 9 (12.3) | 83 (97) | 12 (14) | ||||
| Lobular and others | 10 (9) | 2 (20) | 12 (7) | 1 (8) | 4 (5) | 1 (25) | 3 (3) | 1 (33) | ||||
| Histological grade | - | 0.213 | 0.266 | 1.000 | ||||||||
| G1-G2 | 103 (97) | 12 (12) | 61 (39) | 2 (3) | 23 (30) | 1 (4.3) | 13 (15) | 2 (15) | ||||
| G3 | - | - | 102 (61) | 10 (10) | 53 (69) | 9 (17) | 72 (85) | 10 (14) | ||||
| NR | 4 (3) | 1 (25) | 2 (1) | 0 (0) | 1 (1) | 0 (0) | 1 (0) | 1 (100) | ||||
| Tumor size (cm) | 0.102 | 0.213 | 0.511 | 0.620 | ||||||||
| Median (range) | 6 (2-15) | 5 (2-9) | 7 (2-20) | 6 (2-12) | 7 (2.5-14) | 6 (4-12) | 7 (1-24) | 8 (3-15) | ||||
| cT1-cT2 | 10 (7) | 3 (30) | 12 (7) | 2 (17) | 5 (6) | 1 (20) | 9 (10) | 2 (22) | ||||
| cT3-cT4 | 97 (93) | 10 (10) | 153 (93) | 10 (7) | 72 (94) | 9 (12.5) | 77 (90) | 11 (14) | ||||
| cN | 0.306 | 0.222 | 0.270 | 0.021 | ||||||||
| cN0 | 27 (23) | 5 (19) | 28 (18) | 0 (0) | 53 (69) | 5 (9.4) | 14 (14) | 4 (29) | ||||
| cN1-cN2–cN3 | 80 (77) | 8 (10) | 137 (82) | 12 (9) | 24 (31) | 5 (20.8) | 72 (86) | 9 (13) | ||||
| Clinical stage | 0.471 | 0.652 | 1.000 | 0.122 | ||||||||
| EC II | 23 (20) | 4 (17) | 21 (12) | 2 (10) | 11 (14) | 1 (9.1) | 17 (16) | 5 (29) | ||||
| EC III | 84 (80) | 9 (11) | 144 (88) | 10 (7) | 66 (86) | 9 (13.6) | 69 (84) | 8 (12) | ||||
| sTIL% | 0.054 | 0.750 | 0.150 | 1.000 | ||||||||
| Median (range) | 30 (2-90) | 50 (10-90) | 40 (5-90) | 30 (8-90) | 60 (5-95) | 80 (30-95) | 45 (2-90) | 50 (5-80) | ||||
| < 50 | 71 (69) | 6 (8) | 98 (60) | 6 (6) | 25 (32) | 1 (4) | 40 (47) | 6 (15) | ||||
| ≥ 50 | 30 (24) | 7 (23) | 61 (37) | 5 (8) | 50 (66) | 9 (18) | 40 (47) | 6 (15) | ||||
| Missing data | 6 (6) | 0 (0) | 6 (3) | 1 (17) | 2 (3) | 0 (0) | 6 (7) | 1 (17) | ||||
| TLCS (d) | 0.233 | 0.238 | 0.744 | 0.500 | ||||||||
| Median (range) | 67 (14-458) | 80 (16-281) | 61 (5-412) | 54 (8-140) | 60 (11-240) | 66 (37-106) | 64 (8-982) | 66 (14-122) | ||||
| Shorter than median | 49 (48) | 4 (8) | 77 (45) | 8 (10) | 41 (53) | 5 (12.2) | 40 (48) | 5 (13) | ||||
| Longer than median | 57 (51) | 9 (16) | 76 (47) | 4 (5) | 33 (43) | 5 (15.2) | 45 (51) | 8 (18) | ||||
| Missing data | 1 (1) | 0 (0) | 12 (8) | 0 (0) | 3 (4) | 0 (0) | 1 (1) | 0 (0) | ||||
| Relapse | 0.121 | 0.753 | 0.300 | < 0.001 | ||||||||
| No | 87 (79) | 13 (15) | 109 (65) | 9 (8) | 46 (60) | 8 (17.4) | 42 (41) | 12 (29) | ||||
| Yes | 20 (21) | 0 (0) | 56 (35) | 3 (5) | 31 (40) | 2 (6.5) | 44 (59) | 1 (2) | ||||
- Citation: Galvez M, Castaneda CA, Sanchez J, Castillo M, Rebaza LP, Calderon G, Cruz MDL, Cotrina JM, Abugattas J, Dunstan J, Guerra H, Mejia O, Gomez HL. Clinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy. World J Clin Oncol 2018; 9(2): 33-41
- URL: https://www.wjgnet.com/2218-4333/full/v9/i2/33.htm
- DOI: https://dx.doi.org/10.5306/wjco.v9.i2.33